查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1542895

全球子宫肌瘤治疗市场 - 2024-2031

Global Uterine Fibroids Treatment Market - 2024-2031
出版日期: | 出版商: DataM Intelligence | 英文 200 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

子宫肌瘤治疗市场规模

2023年，全球子宫肌瘤治疗市场规模达13.6341亿美元，预计2031年将达到27.3947亿美元，2024-2031年预测期间复合年增长率为9.4%。

子宫肌瘤是女性子宫最常见的良性非癌性肿瘤，常见于生育期间。肌瘤只有在引起症状时才需要治疗，治疗方案包括药物治疗和侵入性手术。子宫肌瘤治疗市场有巨大的成长机会。全球子宫肌瘤治疗市场主要是由于女性老年人口的增加、荷尔蒙失调的盛行率不断上升以及生活方式的改变而导致患者人数不断增加。

子宫肌瘤治疗市场动态

全球子宫肌瘤治疗市场的主要成长动力是个人疾病意识的提高、高效新技术的发展、全球政府活动的增加、子宫肌瘤发病率的激增以及人们生活方式的改变，以及育龄妇女人数不断增加。

子宫肌瘤发生率的上升推动了全球市场的成长。

子宫肌瘤是女性最常见的骨盆腔肿瘤，在全球发生，盛行率为 21.4%。子宫肌瘤是女性最常见但尚未充分研究的疾病之一。国际妇产科联合会 2020 年资料表明，这些肿瘤（俗称子宫肌瘤）主要影响育龄期女性，高达 70% 的白人女性和超过 80% 的非洲裔女性在一生中被诊断出患有这种肿瘤。这种疾病对全球医疗保健服务和成本产生深远影响。虽然大多数患有子宫肌瘤的女性没有症状，但大约 30% 的女性会出现严重症状，包括异常子宫出血、贫血、骨盆疼痛和压力、背痛、频尿、便秘或不孕，需要介入。在美国，每年约有 650 万名女性因肌瘤寻求治疗，近 1/3 的就业患者 (28%) 报告因肌瘤症状而缺勤。

对治疗方案的认识不足将阻碍市场的成长。

然而，社区和医学界对肌瘤的关注有限，这意味着高风险女性无法获得所需的有关疾病的知识。 《女性健康期刊》2020 年的研究发现，只有 49% 的高风险女性有症状，但并未临床诊断为子宫肌瘤。症状出现后，大多数女性 (60%) 试图自行控制症状或等待症状是否消失 (50%)。即使女性被诊断出子宫肌瘤，她们的治疗选择也是有限的，并且会影响她们的生育能力。女性可以服用非处方非类固醇抗发炎药物 (NSAID) 和对乙酰氨基酚来缓解与子宫肌瘤相关的疼痛，但这些只是暂时缓解骨盆疼痛。某些形式的节育措施可以帮助缓解大量出血，但并不适用于所有女性，也不是尝试怀孕的女性的选择。

COVID-19 对子宫肌瘤治疗市场的影响分析

COVID-19大流行对妇科手术产生了重大影响。美国外科医师学会建议在2020 年3 月之前推迟所有不必要的侵入性手术。研究论文，2019 年共完成了1,545 例妇科手术，与 2020 年的 942 例相比，下降了 39.0%。对全球市场产生负面影响。

子宫肌瘤治疗市场細項分析

在预测期内（2024-2031年），手术方法领域预计将更能掌握子宫肌瘤治疗市场。

2021 年，手术方法细分市场占据最大市场份额。然而，医生通常会建议那些肌瘤引起中度或重度症状（如疼痛或大量出血）的女性接受手术。治疗子宫肌瘤的手术可以包括保留器官或部分或全部器官切除。子宫肌瘤的手术治疗采用三种方法（腹部、腹腔镜、阴道）或三种方法的组合。进行几种类型的外科手术来治疗子宫肌瘤。其中包括子宫内膜消融、MRI 导引手术、子宫切除术、子宫肌瘤切除术、子宫动脉栓塞术 (UAE) 和射频消融术等。其中，子宫切除术在2021年占据了最大的市场。

子宫肌瘤治疗市场地域份额

预计北美将主导全球子宫肌瘤治疗市场。

北美在子宫肌瘤治疗市场上占据主导地位，预计在预测期内（2022-2029年）将呈现类似的趋势。由于其成熟的医疗保健行业，特别是在美国和加拿大，人们的意识不断提高，并且易于获得先进技术。荷尔蒙失调患者数量的增加和子宫癌盛行率的增加是该区域子宫肌瘤治疗市场的关键成长驱动因素。例如，在美国，女性 35 岁时子宫肌瘤的盛行率为 60%，到 50 岁时增加至 80% 以上。

此外，开放式手术的微创有效替代方案的出现、技术进步和频繁的治疗类型创新，加上监管批准的增加和有利的报销政策，预计将推动该地区市场的成长。

子宫肌瘤治疗公司及竞争格局

子宫肌瘤治疗市场是本地和全球公司竞争适度的市场。推动市场成长的一些主要参与者包括波士顿科学公司（Minerva Surgical）、Cooper Surgical, Inc.、奥林巴斯公司、Acessa Health（Halt Medical, Inc.）、Gynesonics、Conmed Corporation、AbbVie Inc.。 、Karl Storz、Richard Wolf GmbH、LiNA Medical USA、Blue Endo 等。主要参与者正在采取多种成长策略，例如治疗类型的推出、收购和合作，为全球市场的成长做出贡献。例如，2020 年 5 月 12 日，Minerva Surgical, Inc 从 Boston Scientific 收购了以下子宫内健康治疗类型：Symphion 组织移除系统； Resectr 组织切除装置；和 Genesys HTA 系统。

波士顿科学公司

概述 ：

该公司成立于1979年，总部位于美国。波士顿科学公司开发、製造和销售微创医疗设备。该公司的治疗类型用于介入性心臟病学、心律管理、週边干预、电生理学、神经血管干预、内视镜检查、泌尿科、妇科和神经调节。

治疗类型组合：

Symphion 组织切除系统：一体化 Symphion 系统旨在改变您切除子宫组织的方式。它将突破性的液体管理、直接子宫内压力监测和无刀切除完美结合在一起。

全球子宫肌瘤治疗报告将提供约 40 多个市场资料表、45 多个数字和 200 多个（约）页数。

目录

第 1 章：方法与范围

第 2 章：市场定义与概述

第 3 章：执行摘要

第 4 章：市场动态

  • 市场影响因素
    • 司机
      • 子宫肌瘤的发生率上升
      • 不断进步的技术
    • 限制
      • 与手术治疗相关的併发症
    • 机会
    • 影响分析

第 5 章：产业分析

  • 波特五力分析
  • 供应链分析
  • 监管分析
  • 流行病学
  • 定价分析
  • 比较分析

第 6 章：COVID-19 分析

第 7 章：按治疗类型

  • 非荷尔蒙治疗：非类固醇类抗发炎药 (NSAID)
  • 荷尔蒙治疗
    • 口服避孕药
    • 黄体素/抗黄体素
    • GnRH 激动剂
  • 手术方法
    • 子宫内膜移除术
    • MRI 导引程式
    • 子宫切除术
    • 子宫肌瘤切除术
    • 子宫动脉栓塞术
    • 射频消融术

第 8 章：按类型

  • 黏膜下层
  • 浆膜下
  • 壁内
  • 有蒂的

第 9 章：最终用户

  • 医院和诊所
  • ASC
  • 伤口护理中心
  • 其他

第 10 章：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 欧洲其他地区
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地区
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳洲
    • 亚太地区其他地区
  • 中东和非洲

第 11 章：竞争格局

  • 主要进展和策略
  • 公司股份分析
  • 产品基准化分析

第 12 章：公司简介

  • Boston Scientific Corporation (Minerva Surgical)
    • 公司概况
    • 产品组合和描述
    • 主要亮点
    • 财务概览
  • Cooper Surgical, Inc.
  • Olympus Corporation
  • Acessa Health (Halt Medical, Inc.)
  • Gynesonics
  • Conmed Corporation
  • AbbVie Inc.
  • Medtronic
  • Karl Storz
  • Richard Wolf GmbH
  • LiNA Medical USA
  • Blue Endo(*LIST NOT EXHAUSTIVE)

第 13 章：数据M

简介目录
Product Code: PH8

Uterine Fibroids Treatment Market Size

The global uterine fibroids treatment market reached US$ 1,363.41 million in 2023 and is expected to reach US$ 2,739.47 million by 2031, growing at a CAGR of 9.4% during the forecast period 2024-2031.

Uterine fibroids are a woman's uterus's most commonly benign, non-cancerous tumors, often seen during childbearing. Fibroids are only treated if they cause symptoms, and treatment options range from medications to invasive surgery. The uterine fibroids treatment market has significant opportunities to grow. The global uterine fibroids treatment market is primarily driven by an increasing patient pool owing to the increasing female geriatric population, the growing prevalence of hormonal disorders, and changing lifestyles.

Uterine Fibroids Treatment Market Dynamics

Major growth drivers of the uterine fibroids treatment market over the globe are an increase in consciousness among individuals about diseases, growth of efficient and new technology, rising government activities over the globe, a surge in occurrence of uterine fibroids, and changed people's lifestyle, and increasing number of women of reproductive age.

The rising incidences of uterine fibroids drive global market growth.

Uterine fibroids are women's most common pelvic tumors, occurring globally, with a prevalence of 21.4%. Uterine leiomyomas are among women's most common yet understudied diseases. The International Federation of Gynecology and Obstetrics 2020 data states that these tumors, commonly known as fibroids, affect women mainly during their reproductive years and are diagnosed in up to 70% of white women and more than 80% of women of African ancestry during their lifetime. This disease has a profound impact on healthcare delivery and costs worldwide. Though most women with fibroids are asymptomatic, approximately 30% will present with severe symptoms, including abnormal uterine bleeding, anemia, pelvic pain and pressure, back pain, urinary frequency, constipation, or infertility, and will require intervention. Every year in the United States, approximately 6.5 million women seek treatment for fibroids, and nearly 1/3 of employed patients (28%) report missing work days due to fibroid symptoms.

The low awareness of treatment options will hamper the growth of the market.

However, limited attention to fibroids in the community and the medical society means that at-risk women do not have access to the knowledge they need regarding the disease. The 2020 study in the Journal of Women's Health uncovered that only 49% of at-risk women with manifestations suggest fibroids but not a clinical diagnosis of uterine fibroids. Following the onset of their symptoms, most of these women (60%) tried to manage symptoms themselves or waited to see if the symptoms went away (50%). Even when women receive a fibroid diagnosis, their treatment options are limited and affect their fertility. Women can take over-the-counter nonsteroidal anti-inflammatory drugs (NSAIDs) and acetaminophen to alleviate pain associated with uterine fibroids, but these are just momentary fixes for pelvic pain. Some forms of birth control can help alleviate heavy bleeding but don't work for all women and are not an option for women trying to get pregnant.

COVID-19 Impact Analysis on Uterine Fibroids Treatment Market

The COVID-19 pandemic had a significant impact on gynecological surgery. The American College of Surgeons has recommended delaying all unnecessary invasive surgery by March 2020. According to a December 2021 research paper titled analysis of response and effects impact of COVID-19 on gynaecological surgery in major university hospitals, 1,545 gynecologic cases were done in 2019, compared to 942 cases in 2020, suggesting a 39.0% decline. Negatively impacting the global market.

Uterine Fibroids Treatment Market Segmentation Analysis

The surgical methods segment is expected to have a greater grasp of the uterine fibroids treatment market during the forecast period (2024-2031).

The surgical methods segment accounts for the largest market share in 2021. Medications can help if the symptoms are mild. However, doctors usually recommend procedures for women whose fibroids cause moderate or severe symptoms, like pain or heavy bleeding. Surgery to treat uterine fibroids can include organ preservation or involve partial or total organ removal. Three approaches (abdominal, laparoscopic, vaginal) or a combination of the three are used for the surgical treatment of uterine fibroids. Several types of surgical procedures are performed for the treatment of uterine fibroids. Dome of them includes endometrial Ablation, MRI Guided Procedures, Hysterectomy, Myomectomy, Uterine Artery Embolization (UAE), and Radiofrequency Ablation, among others. Among these, Hysterectomy accounted for the largest market share in 2021.

Uterine Fibroids Treatment Market Geographical Share

North America is expected to dominate the global uterine fibroids treatment market.

North America dominates the market for uterine fibroids treatment and is expected to show a similar trend over the forecast period (2022-2029). Owing to its established healthcare industry, particularly in the U.S. and Canada, increased awareness, and easy accessibility to advanced technologies. The increased patient pool undergoing hormonal disorders and increasing prevalence of uterine cancer is the key growth driving factor for this regional uterine fibroid treatment market. For instance, in the USA, the prevalence of uterine fibroids was 60% at age 35, which increased to more than 80% by 50 years among women.

Moreover, the advent of minimally invasive and effective alternatives to open surgeries, technological advancements, and frequent Treatment Type innovations coupled with an increase in regulatory approvals and favorable reimbursement policies are expected to boost the market's growth in the region.

Uterine Fibroids Treatment Companies and Competitive Landscape

The uterine fibroids treatment market is a moderately competitive presence of local and global companies. Some of the key players which are contributing to the growth of the market are Boston Scientific Corporation (Minerva Surgical), Cooper Surgical, Inc., Olympus Corporation, Acessa Health (Halt Medical, Inc.), Gynesonics, Conmed Corporation, AbbVie Inc., Medtronic, Karl Storz, Richard Wolf GmbH, LiNA Medical USA, Blue Endo among others. The major players are adopting several growth strategies, such as Treatment Type launches, acquisitions, and collaborations, contributing to the global market growth. For instance, in May 12, 2020, Minerva Surgical, Inc, acquired the following Intrauterine Health Treatment Types from Boston Scientific: the Symphion Tissue Removal System; the Resectr Tissue Resection Device; and the Genesys HTA System.

Boston Scientific Corporation

Overview:

The company was founded in 1979. It has headquarters in the United States. Boston Scientific Corporation develops, manufactures, and markets minimally invasive medical devices. The Company's Treatment Types are used in interventional cardiology, cardiac rhythm management, peripheral interventions, electrophysiology, neurovascular intervention, endoscopy, urology, gynecology, and neuromodulation.

Treatment Type Portfolio:

Symphion Tissue Removal System: The all-in-one Symphion System is designed to transform how you remove uterine tissue. It unites breakthrough fluid management, direct intrauterine pressure monitoring, and bladeless resection to work together perfectly.

The global uterine fibroids treatment report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rising Incidences of Uterine Fibroids
      • 4.1.1.2. Increasing Technological Advancements
    • 4.1.2. Restraints
      • 4.1.2.1. Complications Associated with Surgical Treatments
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Regulatory Analysis
  • 5.4. Epidemiology
  • 5.5. Pricing Analysis
  • 5.6. Comparative analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Treatment Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type Segment
    • 7.1.2. Market Attractiveness Index, By Treatment Type Segment
  • 7.2. Non-hormonal Treatment: Non-steroidal Anti-inflammatory Agents (NSAIDs)
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Hormonal Treatment
    • 7.3.1. Oral contraceptives
    • 7.3.2. Progestins/Antiprogestins
    • 7.3.3. GnRH Agonists
  • 7.4. Surgical Methods
    • 7.4.1. Endometrial Ablation
    • 7.4.2. MRI Guided Procedures
    • 7.4.3. Hysterectomy
    • 7.4.4. Myomectomy
    • 7.4.5. Uterine Artery Embolization
    • 7.4.6. Radiofrequency Ablation

8. By Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type Segment
    • 8.1.2. Market Attractiveness Index, By Type Segment
  • 8.2. Submucosal
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Subserosal
  • 8.4. Intramural
  • 8.5. Pedunculated

9. By End User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User Segment
    • 9.1.2. Market Attractiveness Index, By End User Segment
  • 9.2. Hospitals And Clinics
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. ASCs
  • 9.4. Wound Care Centers
  • 9.5. Other

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. The U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. The U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.7.1. Brazil
      • 10.4.7.2. Argentina
      • 10.4.7.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

11. Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Product Benchmarking

12. Company Profiles

  • 12.1. Boston Scientific Corporation (Minerva Surgical)
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Cooper Surgical, Inc.
  • 12.3. Olympus Corporation
  • 12.4. Acessa Health (Halt Medical, Inc.)
  • 12.5. Gynesonics
  • 12.6. Conmed Corporation
  • 12.7. AbbVie Inc.
  • 12.8. Medtronic
  • 12.9. Karl Storz
  • 12.10. Richard Wolf GmbH
  • 12.11. LiNA Medical USA
  • 12.12. Blue Endo(*LIST NOT EXHAUSTIVE)

13. DataM Intelligence

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us